Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran

Alnylam Pharmaceuticals, Inc. ALNY, a leading RNAi therapeutics company, announced today that it has earned a $7 million milestone from its partner Genzyme, a Sanofi SNY company, for achieving Phase II success with patisiran (ALN-TTR02). Alnylam recently presented positive Phase II results at the IXth International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP) held in Rio de Janeiro, Brazil, November 10 – 13. Results showed that multiple doses of patisiran led to robust and statistically significant knockdown of serum TTR protein levels of up to 96%, with mean levels of TTR knockdown exceeding 85%. Knockdown of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, and durable, and similar activity was observed toward See full press release